Ixtlan Bioscience, a biotech company focused on developing psilocybin-based treatment for Alzheimer’s Disease and Brain Pathologies, has announced today the filing of a new Provisional Patent with the United States Patent and Trademark Office Application No. 63279349 – named; Ixtlan AD Kit, which is a novel treatment for Alzheimer’s and neuronal disorders.
Compound Psilocybin
Visit article
Category Press Release
Country Israel
Companies Featured
IxtlanIxtlan Biosciences was an Israeli-based biotech company working with natural psilocybin mushrooms in the field of Alzheimer's and dementia diseases.